Appeals Court Rejects GlaxoSmithKline's Bid for Augmentin Patent
The U.S. Court of Appeals for the Federal Circuit on Friday rejected GlaxoSmithKline Plc's bid to salvage patent protection for its antibiotic Augmentin....To view the full article, register now.
Already a subscriber? Click here to view full article